Recurrence Rate, Clinical Outcome, and Cellular Proliferation: Indices as Prognostic Indicators after Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors: 28 Dogs (1994–2002)
- 1 July 2006
- journal article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 20 (4) , 933-940
Abstract
The objectives of this study were to determine local recurrence rate, clinical outcome, and prognostic value of the number of argyrophylic nucleolar organizer regions (AgNORs), presence of proliferating cell nuclear antigen (PCNA), and number of Ki-67-positive nuclei after incomplete surgical excision of canine cutaneous grade II mast cell tumors (MCTs). This retrospective study included 30 MCTs in 28 dogs. Medical records were examined and follow-up information was obtained from owners and referring veterinarians. Only cases in which excision was incomplete and no anvcillary therapy (other than prednisone) for MCT was given were included. Paraffin-embedded tumor tissues were retrieved for AgNORs, PCNA, and Ki-67 staining. Median follow-up time was 811.5 days. Seven (23.3%) tumors recurred locally. Median time to local recurrence was not reached with a mean of 1,713 days. The estimated proportions of tumors that recurred locally at 1,2, and 5 years were 17.3, 22.1, and 33.3%, respectively. Eleven (39.3%) dogs developed MCTs at other cutaneous locations. Median progression-free survival was 1,044 days. Median overall survival was 1,426 days. The combination of Ki-67 and PCNA scores was prognostic for local recurrence (P= .03) and development of local recurrence was prognostic for decreased overall survival (P= .04). Results suggest that a minority of incompletely excised MCTs recur. Therefore, ancillary local therapies may not always be necessary. However, local recurrence can negatively affect survival of the affected dogs. Cellular proliferation indices may indicate the likelihood of MCT recurrence after incomplete excision.Keywords
This publication has 25 references indexed in Scilit:
- Vinblastine and Prednisolone as Adjunctive Therapy for Canine Cutaneous Mast Cell TumorsJournal of the American Animal Hospital Association, 2004
- Mast cell tumors in the dogVeterinary Clinics of North America: Small Animal Practice, 2003
- Prognosis Following Surgical Excision of Canine Cutaneous Mast Cell Tumors With Histopathologically Tumor-Free Versus Nontumor-Free Margins: A Retrospective Study of 31 CasesJournal of the American Animal Hospital Association, 2002
- Recurrence Rates and Sites for Grade II Canine Cutaneous Mast Cell Tumors Following Complete Surgical ExcisionJournal of the American Animal Hospital Association, 2002
- Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993)Journal of the American Animal Hospital Association, 1997
- Prognosis of Canine Mast Cell Tumors: A Comparison of Three MethodsVeterinary Pathology, 1994
- Incomplete surgery, local immunostimulation, and recurrence of some tumour types in dogs and catsVeterinary Quarterly, 1987
- Canine Mast Cell TumorsVeterinary Clinics of North America: Small Animal Practice, 1985
- The prognosis following surgical removal of mastocytomas in dogsJournal of Small Animal Practice, 1973
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958